Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO) - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Oncology Année : 2020

Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)

Mayssam El Mouhebb
  • Fonction : Auteur
Antonio Di Meglio
; Mayssam
  • Fonction : Auteur
El Mouhebb
  • Fonction : Auteur
Suzette Delaloge
Charles Coutant
Paul Cottu
Anne Lesur
Florence Lerebours
Olivier Tredan
  • Fonction : Auteur
Laurence Vanlemmens
Christelle Levy
Jerome Lemonnier
  • Fonction : Auteur
Christelle Mesleard
  • Fonction : Auteur
Fabrice Andre
  • Fonction : Auteur
Gwenn Menvielle

Résumé

PURPOSE Adverse effects of breast cancer treatment can negatively affect survivors’ work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact of treatment and related sequelae on employment. METHODS We used a French prospective clinical cohort of patients with stage I-III breast cancer including 1,874 women who were working and ≥ 5 years younger than legal retirement age (≤ 57 years) at breast cancer diagnosis. Our outcome was nonreturn to work (non-RTW) 2 years after diagnosis. Independent variables included treatment characteristics as well as toxicities (Common Toxicity Criteria Adverse Events [CTCAE] v4) and PROs (European Organization for Research and Treatment of Cancer [EORTC] Quality of life Questionnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depression Scale) collected 1 year after diagnosis. Logistic regression models assessed correlates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates. RESULTS Two years after diagnosis, 21% of patients had not returned to work. Odds of non-RTW were significantly increased among patients treated with combinations of chemotherapy and trastuzumab (odds ratio [OR] v chemotherapy-hormonotherapy: for chemotherapy-trastuzumab, 2.01; 95% CI, 1.18 to 3.44; for chemotherapy-trastuzumab-hormonotherapy, 1.62; 95% CI, 1.10 to 2.41). Other significant associations with non-RTW included grade ≥ 3 CTCAE toxicities (OR v no, 1.59; 95% CI, 1.15 to 2.18), arm morbidity (OR v no, 1.59; 95% CI, 1.19 to 2.13), anxiety (OR v no, 1.47; 95% CI, 1.02 to 2.11), and depression (OR v no, 2.29; 95% CI, 1.34 to 3.91). CONCLUSION Receipt of systemic therapy combinations including trastuzumab was associated with increased odds of non-RTW. Likelihood of unemployment was also higher among patients who reported severe physical and psychological symptoms. This comprehensive study identifies potentially vulnerable patients and warrants supportive interventional strategies to facilitate their RTW.
Fichier principal
Vignette du fichier
Dumas et al JCO 2019 RTW after BC.pdf (684.11 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03088680 , version 1 (26-12-2020)

Identifiants

Citer

Ines Vaz Luis, Mayssam El Mouhebb, Antonio Di Meglio, Agnès Dumas, Inês Matias Luís, et al.. Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). Journal of Clinical Oncology, 2020, 38 (7), pp.734-743. ⟨10.1200/jco.19.01726⟩. ⟨hal-03088680⟩
101 Consultations
76 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More